Cambridge Investment Research Advisors
HRTX icon

Cambridge Investment Research Advisors’s Heron Therapeutics HRTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
27,995
+5,698
+26% +$4.57K ﹤0.01% 4028
2026
Q1 		$18K Sell
22,297
-4,125
-16% -$4.78K ﹤0.01% 3896
2025
Q4 		$34K Sell
26,422
-200
-0.8% -$247 ﹤0.01% 3772
2025
Q3 		$34K Sell
26,622
-1,345
-5% -$2.13K ﹤0.01% 3671
2025
Q2 		$58K Buy
27,967
+100
+0.4% +$204 ﹤0.01% 3528
2025
Q1 		$61K Buy
27,867
+17,500
+169% +$34K ﹤0.01% 3393
2024
Q4 		$16K Sell
10,367
-1,300
-11% -$2.11K ﹤0.01% 3432
2024
Q3 		$23K Sell
11,667
-3,200
-22% -$7.64K ﹤0.01% 3361
2024
Q2 		$52K Buy
14,867
+4,000
+37% +$12.3K ﹤0.01% 3215
2024
Q1 		$30K Sell
10,867
-1,000
-8% -$2.51K ﹤0.01% 3247
2023
Q4 		$20K Sell
11,867
-3,750
-24% -$4.13K ﹤0.01% 3143
2023
Q3 		$16K Sell
15,617
-1,900
-11% -$2.7K ﹤0.01% 3092
2023
Q2 		$20K Sell
17,517
-500
-3% -$892 ﹤0.01% 3125
2023
Q1 		$27K Buy
18,017
+700
+4% +$1.75K ﹤0.01% 3084
2022
Q4 		$43K Sell
17,317
-1,000
-5% -$3.22K ﹤0.01% 2996
2022
Q3 		$77K Hold
18,317
– – ﹤0.01% 2893
2022
Q2 		$51K Sell
18,317
-1,500
-8% -$6.02K ﹤0.01% 2940
2022
Q1 		$113K Buy
19,817
+41
+0.2% +$300 ﹤0.01% 2999
2021
Q4 		$181K Buy
19,776
+4,540
+30% +$46.4K ﹤0.01% 2917
2021
Q3 		$163K Buy
15,236
+31
+0.2% +$377 ﹤0.01% 2860
2021
Q2 		$236K Buy
+15,205
New +$242K ﹤0.01% 2675

Other funds holding HRTX

Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Cambridge Investment Research Advisors's HRTX Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Heron Therapeutics (HRTX) stake by 26% in Q2 2026, buying an estimated $4.57K and bringing the position to 27,995 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #4028.

Cambridge Investment Research Advisors first reported a position in HRTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $236K in Q2 2021. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Cambridge Investment Research Advisors held 27,995 shares of Heron Therapeutics worth $12K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 5,698 Heron Therapeutics shares in Q2 2026, an estimated $4.57K.
  • Heron Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #4028 holding.
  • Cambridge Investment Research Advisors first reported a position in Heron Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Cambridge Investment Research Advisors's Heron Therapeutics position peaked at $236K in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.